Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Major Depression Disorder Clear all
Completed Phase 3 Interventional

Duloxetine Versus Placebo for Fibromyalgia

NCT00489073
View directory record Official record
Conditions
Fibromyalgia
Interventions
duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 20, 2007 · Synced Sep 21, 2026, 3:56 PM EDT
Terminated Not applicable Interventional Results available

Cysteamine Therapy for Major Depressive Disorder

NCT00715559
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
cysteamine bitartrate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436162
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Antidepressant + Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 21, 2026, 3:56 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Schizoaffective Disorder Using Mifepristone

NCT00725270
View directory record Official record
Conditions
Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
Interventions
Mifepristone, Placebo Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

NCT01670279
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
70 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Kissimmee, Florida • Miami, Florida • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 21, 2026, 3:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Depression and Dopamine Transporter Function Study Using C-11 Altropane

NCT01701141
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Not applicable Interventional

Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients

NCT02088580
View directory record Official record
Conditions
Non-Psychotic Unipolar Depression, Bipolar Depression
Interventions
Triple Chronotherapy
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 2 Interventional

Pilot Decentralized Trial

NCT05419869
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALTO-100 PO Tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Coral Gables, Florida • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 4 Interventional

Thyroid Medication and Antidepressants for Treating Major Depression

NCT00208702
View directory record Official record
Conditions
Major Depression
Interventions
Triiodothyronine, Placebo, Sertraline
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 2 Interventional

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

NCT06423781
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
66
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 21, 2026, 3:56 PM EDT
Not listed Phase 1Phase 2 Interventional

Altering Default Mode Network Activity With Transcranial Focused Ultrasound to Reduce Depressive Symptoms

NCT06320028
View directory record Official record
Conditions
Depressive Disorder, Major, Depression
Interventions
Non-Invasive Transcranial Focused Ultrasound
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Not applicable Interventional Results available

Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder

NCT01415154
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NeuroStar TMS
Device
Lead sponsor
Neuronetics
Other
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Chicago, Illinois • Baltimore, Maryland • Lincoln, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 21, 2026, 3:56 PM EDT
Completed No phase listed Observational

Brain Function in Mentally Ill Adolescents

NCT00025857
View directory record Official record
Conditions
Healthy, Posttraumatic Stress Disorder, Major Depressive Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 4 Interventional

Electroencephalography (EEG) Biomarkers of Response in Depression

NCT00759122
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
venlafaxine (Effexor), placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2008 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Females

NCT01373931
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Ortho Cyclen, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 3 Interventional

Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder

NCT00278941
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine Fumarate Sustained Release
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
144
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 21, 2026, 3:56 PM EDT
Completed No phase listed Observational

Deciphering Principles of Network Dynamics Underlying Depression Symptom Severity From Multi-day Intracranial Recordings in Patients With Major Depression

NCT06953362
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Direct Neural Electrical Stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Months to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 21, 2026, 3:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Psychological Development of Children of Parents With and Without Affective Disorders

NCT00001170
View directory record Official record
Conditions
Bipolar Disorder, Involutional Depression, Mood Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
1,045 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1979 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 21, 2026, 3:56 PM EDT
Recruiting No phase listed Observational

An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms

NCT07329673
View directory record Official record
Conditions
Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)
Interventions
Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)
Device
Lead sponsor
Qbtech AB
Industry
Eligibility
6 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Test a New Drug to Treat Major Depression

NCT00976560
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
GW856553, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Hoffman Estates, Illinois • Park Ridge, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 21, 2026, 3:56 PM EDT
Enrolling by invitation No phase listed Observational

Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements

NCT06002100
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
fNIRS measurement
Other
Lead sponsor
Kernel
Industry
Eligibility
18 Years to 75 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Costa Mesa, California • La Jolla, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Not applicable Interventional

PRISM Neurofeedback Training for MDD Anhedonic Patients

NCT05869708
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Active RS-EFP, Sham RS-EFP
Device
Lead sponsor
GrayMatters Health Ltd.
Industry
Eligibility
22 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 21, 2026, 3:56 PM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 4 Interventional

Sleep Deprivation Plus Paroxetine for Treating Major Depression in Elderly Individuals

NCT00178035
View directory record Official record
Conditions
Depression
Interventions
paroxetine, One night of Total Sleep Deprivation
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 21, 2026, 3:56 PM EDT